Venous thromboembolism: Risk factors and prophylaxis

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 6, 2000, Pages 493-501

  Selby, R ^a   Geerts, W H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Prophylaxis; Risk factors; Thromboembolism

Indexed keywords

HEPARIN; WARFARIN;

DRUG CHOICE; DRUG INDICATION; EMBOLISM PREVENTION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN DISEASE;

EID: 0034520526     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13189     Document Type: Review

References (73)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT study
2. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
3. Deep vein thrombosis and pulmonary embolism in the general population: "The study of men born in 1913"
4. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study
5. Prevention of venous thromboembolism
6. Prevention of venous thromboembolism
7. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study
8. A prospective study of venous thromboembolism after major trauma
9. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip
10. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
11. Deep venous thrombosis and occult malignancy: An epidemiological study
12. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
13. Pathophysiology of the thrombophilic state in the cancer patient
14. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
15. Cancer and venous thromboembolism
16. Venous thromboembolism as first manifestation of cancer
17. Venous thromboembolism and cancer
18. The long-term clinical course of acute deep venous thrombosis
19. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study
20. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women
21. Risk factors for pregnancy associated venous thromboembolism
22. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism?
23. Safety of withholding antepartum heparin despite previous thromboembolism (VTE)
24. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
25. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias
26. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
27. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study
28. Risk factors for venous thrombotic disease
29. Fatal pulmonary embolism in hospitalised medical patients
30. The relationship of fatal pulmonary insufficiency with cor pulmonale, right sided mural thrombi and pulmonary emboli: A preliminary report
31. Pulmonary embolism and thrombosis in chronic obstructive emphysema
32. Clinical and morphologic correlations in chronic airway obstruction
33. Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit
34. Pulmonary embolism and mortality in patients with COPD
35. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD
36. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease
37. Travel as a risk factor for venous thromboembolic disease. A case-control study
38. Smoking and abdominal obesity. Risk factors for venous thromboembolism among middle-aged men: "The Study of men born in 1913"
39. Syndromes of thrombosis and hypercoagulability: Congenital and acquired thrombophilias
40. Molecular risk factors for thrombosis
41. World distribution of factor V Leiden
42. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
43. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
44. Geographic distribution of the 20210 G to A prothrombin variant
45. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
46. Antiphospholipid syndrome and thrombosis
47. Many faces of lupus anticoagulants
48. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
49. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
50. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease
51. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: More evidence from a case-control study
52. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
53. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects
54. Risk of and prophylaxis for venous thromboembolism in hospital patients
55. Cost-effectiveness of prophylaxis in total hip replacement
56. Cost-effectiveness of venous thromboembolism prophylaxis in surgery
57. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analyses
58. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective
59. Thromboembolism in gynaecological surgery
60. Prevention and treatment of thrombo-embolic disease in gynaecological surgery
61. Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery
62. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery
63. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
64. Prevention of venous thromboembolism after neurosurgery
65. Prophylaxis of venous thromboembolism following orthopedic surgery: Mechanical and pharmacological approaches and the need for extended prophylaxis
66. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin
67. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery versus warfarin in hip arthroplasty patients: A double-blind, randomized comparison
68. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty
69. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
70. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
71. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A metaanalysis of randomised clinical trials
72. A clinical decision support system for prevention of venous thromboembolism. Effect on physician behavior